Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

PSA Progression: early-phase trial registry

A small indexed set (6 trials) with no open enrollment listed right now.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count

PSA Progression: 6 US clinical trials tracked, none currently recruiting.

PSA Progression is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition psa-progression

OPEN 0 | RECR 0% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%PSA Progression (this)0%
Open-enrollment share among volume-matched conditions near PSA Progression

PSA Progression has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for PSA Progression on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. PSA Progression is recruiting below its size-band peers.

    0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates PSA Progression research.

    Jonsson Comprehensive Cancer Center accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical PSA Progression enrolment sits around 133 participants.

    Median target enrolment is 133 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. PSA Progression research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 26

Phase Distribution

PhaseTrial count
Phase 2 6

Named interventions

Most-linked intervention names on PSA Progression records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
2 trials
Laboratory Biomarker Analysis Other
2 trials
Carboplatin Drug
2 trials
Gallium Ga 68-labeled PSMA-11 Drug
1 trials
White Button Mushroom Extract Drug
1 trials
Patient Observation Other
1 trials
Cabazitaxel Drug
1 trials
Abiraterone Acetate Drug
1 trials

US sites by state

Facility locations filed on PSA Progression trials. A trial with sites in several states counts in each.

California 3 trials
Washington 1 trials
Texas 1 trials
Oregon 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this PSA Progression page

6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This PSA Progression condition card totals 6 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.